CCCC
NASDAQ · Biotechnology
C4 Therapeutics Inc
$4.24
+0.16 (+3.92%)
Open$4.07
Previous Close$4.08
Day High$4.32
Day Low$3.90
52W High$5.17
52W Low$1.69
Volume—
Avg Volume2.33M
Market Cap497.64M
P/E Ratio—
EPS$-1.18
SectorBiotechnology
Analyst Ratings
Strong Buy
13 analysts
Price Target
+825.5% upside
Current
$4.24
$4.24
Target
$39.24
$39.24
$29.92
$39.24 avg
$50.68
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 50.89M | 48.49M | 17.10M |
| Net Income | -148,657,215 | -127,481,175 | 3.03M |
| Profit Margin | -292.1% | -277.5% | 17.7% |
| EBITDA | -160,370,455 | -145,166,205 | 5.37M |
| Free Cash Flow | — | — | 3.54M |
| Rev Growth | +5.0% | +5.0% | +6.2% |
| Debt/Equity | — | — | 1.00 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $249.46 | -0.54% | 70.2 | 443.23B |
| AMGN | Amgen Inc | $415.21 | -0.63% | 25.8 | 225.90B |
| GILD | Gilead Sciences Inc | $138.36 | +0.16% | — | 169.87B |
| VRTX | Vertex Pharmaceuticals Inc | $505.75 | -2.07% | 30.7 | 135.24B |
| REGN | Regeneron Pharmaceuticals | $803.48 | -0.31% | 19.0 | 82.16B |
| ALNY | Alnylam Pharmaceuticals Inc | $228.65 | +0.67% | 37.6 | 30.39B |